Vaccination with Fendrix of prior nonresponding patients with HIV has a high success rate by Machiels, J.D. et al.
CONCISE COMMUNICATIONVaccination with Fendrix of prior nonresponding
patients with HIV has a high success rate
Julian D. Machielsa,M, Esmee E. Braamb,M, Petra van Bentuma,
Miche`le van Vugtc, Theodora E.M.S. de Vries-Sluijsd,
Ineke W.E.M. Schoutene, Wouter F.W. Biermanf
and Elisabeth H. GisolfaaRijnstate Arnhem
Rotterdam, eOLVG
Correspondence t
P.O. Box 9101, 6
Tel: +31 2436143

Julian D. Machie
Received: 23 Aug
DOI:10.1097/QAD
ISSNBackground: Patients with HIV have a poor serological conversion rate with the
standard vaccination strategy against hepatitis B virus (HBV) of around 50%. Vaccina-
tion with Fendrix confers much better results in these patients. In this study, we tested
the effect of revaccination with Fendrix in prior nonresponding patients with HIV and
aimed to determine which factors are associated with seroconversion.
Methods: Eight Dutch HIV treatment centers participated in this retrospective study.
Patients infected with HIV-1 and nonresponding to prior course of vaccination against
HBV (anti-HBs <10 IU/ml) and who had Fendrix as a second, third or fourth effort to
achieve seroconversion were eligible for inclusion. Primary outcome was the propor-
tion of patients with seroconversion after revaccination with Fendrix. Univariate binary
logistic regression analyses were used to determine which factors could be used as
predictors for seroconversions.
Results: We included 100 patients with HIV. Themean age was 47.3 (11.0) years and
86%weremen. Revaccinationwith Fendrix showed a seroconversion rate of 81% (95%
confidence interval 72–88%). Median nadir CD4þ cell count was 300 (20–1040) cells/
ml and median CD4þ cell count at the time at starting vaccination with Fendrix was 605
(210–1190) cells/ml. Regression analyses showed no significant factor associated with
seroconversion.
Conclusions: Revaccination with Fendrix of patients prior nonresponding to other
hepatitis B vaccination strategies has a high success rate. Eighty-one percentage
responded with seroconversion, irrespective of CD4þ cell count.
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Worldwide, an estimated 10% of the 34 million patients
with HIV have chronic hepatitis B virus (HBV) co-
infection [1]. In countries with a low prevalence of
chronic HBV infection, the high rate of co-infection with
HBV is due to the shared transmission route including
sexual contact and intravenous drug use. Patients with
HIV harbor an increased risk of hepatitis B becoming
chronic. The prevalence of chronic HBV infection in the
Netherlands in 2013 was 6.8 per 100 000 [2]. HBV co-
infection was reported in 7% of the Dutch patients with
HIV in 2017 [3]. Individuals with chronic HBV infection
have an increased risk of developing cirrhosis, liver failure
or hepatocellular carcinoma [4–6].
The Guidelines for the Prevention and Treatment of
Opportunistic Infections in HIV-infected Adults and
Adolescents released by the National Institutes of Health,
the Centers for Disease Control and Prevention and the
HIV Medicine Association of the Infectious Diseases
Society of America recommend that all patients with HIV
and without chronic HBV or immunity to HBV should
be vaccinated against HBV [7]. Hepatitis B vaccine
intramuscular or combined hepatitis A virus (HAV) and
hepatitis B vaccine (Twinrix) as a three or four-dose series
are recommended for protection against HBV [7]. In the
Netherlands, hepatitis B vaccination is available free of
charge for risk groups (e.g. sex workers, injecting drug
users and MSM).
A review of the immunological response after hepatitis B
vaccination in adults with HIV reported a wide diversity
of seroconversion after the standard schedule of vaccina-
tion, ranging from 34 to 88.6% [8]. A study performed by
Launay et al. [14] reported a seroconversion rate of 82%
when vaccinated with four double doses intramuscular. A
previous study in the Netherlands has shown that only
50% of patients with HIV have an antibody response to
the initial hepatitis B vaccination consisting of three doses
of 10mg of HBvaxPro, given when the CD4þ cell count
is above 350 cells/ml [9]. Lower nadir CD4þ cell count,
older age, uncontrolled HIV replication and obesity (BMI
>30 kg/m2) are factors associated with a worse response
to HBV vaccination [10–12].
To increase the response to hepatitis B revaccination
in nonresponding patients with HIV, it is best to
postpone the revaccination until the viral load is
undetectable as a result of the use of antiretroviral
therapy (ART) or the CD4þ cell count is above 350 cells/
ml [13]. There are several revaccination strategies,
including giving a double dose vaccine at 0, 1 and 2-
month schedule, or a 0, 1 and 6-month schedule
[7,13,14]. Another strategy is to revaccinate with
Twinrix [7]. Between 4 and 6 weeks after completion
of the vaccine series, it is advised to measure anti-HBs
titer due to diminished response. Copyright © 2019 Wolters Kluwer HFendrix contains 20mg recombinant HB surface antigen,
and in contrast to other HBV vaccines, the adjuvant AS04
– a Toll-like receptor 4 (TLR4) agonist and aluminium
phosphate. TLR4 agonists promote cytokine release and
increase the number of activated antigen presenting cells,
leading to a larger antigen-specific T-cell activation [16].
Since 2005, it has been licensed in Europe for patients
with renal insufficiency older than 15 years, but it is not
licensed for patients with HIV. A previous study has
shown that revaccination with Fendrix in immunocom-
petent persons performed significantly better compared
to the revaccination scheme using three Engerix-B doses
[15]. To our knowledge, only one study exists that studied
the effect of Fendrix as a revaccination strategy in patients
with HIV. However, this is a small study that included
only 22 patients who showed a seroconversion rate of
81.8% [16]. The aim of this study was to describe the
experience with revaccination with Fendrix in patients
with HIV in Dutch HIV treatment centers and to
determine which factors are associated with seroconver-
sion after revaccination.Methods
We conducted a retrospective multicenter study. All the
Dutch HIV treatment centers, including university
medical centers and large regional hospitals that had
used Fendrix as a revaccination strategy, were asked to
participate. Patients infected with HIV-1 and nonre-
sponding to prior vaccination against HBV (defined as
anti-HBs <10 IU/ml), and who had Fendrix as a second,
third of fourth effort to achieve adequate anti-HBV titers
were eligible for inclusion.
Two of the participating centers were visited by one of the
investigators (E.E.B. or Pv.B.) to obtain the required data
by using electronic patient files. In the other centers, the
data were collected by one of the treating physicians and
forwarded anonymously by e-mail.
Sex, country of birth, nadir CD4þ cell count (defined as
the lowest CD4þ cell count measured at any point in
time, but before start of vaccination with Fendrix), the
date started with ART, the type of vaccine given, the
vaccination scheme, the dosage and whether a patient
showed seroconversion after revaccination were
recorded. Age, length, weight, BMI, CD4þ cell count
and viral load, seroconversion after revaccination with
Fendrix, type of ART (e.g. protease inhibitor-based,
non-nucleoside reverse transcriptase inhibitor-based,
integrase inhibitor based) and the revaccination scheme
(e.g. 0, 1, 2, 6 months) were also recorded.
Univariate binary logistic regression was used to
determine which factors could be used as predictors
for a successful seroconversion (anti-HBs 10 IU/ml)ealth, Inc. All rights reserved.
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SPSS, version 23 (IBM Corp., Armonk, NY, USA). All
data are reported as mean standard deviation, or as
median and range. Missing data were treated as missing.
Confidence intervals (CI) for proportions were calculated
using the exact Clopper–Pearson method.
The Medical Ethics Committee of the University
Medical Center Groningen (UMCG) concluded
that this study was in accordance with Dutch Law
(METc 2015/367) and does not meet the criteria of
the Medical Research Involving Human Subjects Act
(WMO).Results
Eight HIV treatment centers agreed to participate and had
used Fendrix as a revaccination strategy. Of these eight
hospitals, five were university medical centers and three
were large regional hospitals. We received data of 100
patients with HIV who were all revaccinated with
Fendrix and these patients were included. They were Copyright © 2019 Wolters Kluwe
Table 1. Baseline characteristics (NU100).
Variable
Male sex (n¼100), n (%)
Age (n¼100) (years, mean)
Dutch nationality (n¼99), n (%)
Median BMI (n¼100, kg/m2) (range)
Median years on treatment before starting with Fendrix (n¼87), (range)
Median CD4þ nadir before vaccination with Fendrix (n¼99, cells/ml) (ran
Viral load at time of Fendrix of <50 copies/ml (n¼95), n (%)
Median CD4þ at time of vaccination with Fendrix (n¼96, cells/ml) (range
Median CD8þ at time of vaccination with Fendrix (n¼76, cells/ml) (range
Patients with CD4þ <350 cells/ml at time of vaccination with Fendrix (n¼
Patients with CD4þ 350 cells/ml at time of vaccination with Fendrix (n¼
Type of vaccine used for first vaccine series (n¼80)
First vaccine series with Engerix, n (%)
First vaccine series with Twinrix, n (%)
First vaccine series with HbVaxPro, n (%)
First vaccine series with other, n (%)
Type of ART used (n¼97)
ART PI-based, n (%)
ART NNRTI/NRTI, n (%)
ART PI-basedþ NNRTI/NRTI, n (%)
ART other, n (%)
No ART, n (%)
Number of previous vaccines series before Fendrix (n¼89)
Fendrix as second vaccine after prior vaccination, n (%)
Fendrix as third vaccine after prior vaccination, n (%)
Fendrix as >third vaccine after prior vaccination, n (%)
Vaccination scheme used for Fendrix (n¼87)
Fendrix scheme 0 month, n (%)
Fendrix scheme 0–1–6 month, n (%)
Fendrix scheme 0–1–2–6 month, n (%)
Fendrix scheme other, n (%)
Response to Fendrix (n¼100, anti-HBs >10 IU/ml), n (%)
Data are reported as mean SD or asmedianwith range. ART, antiretroviral
nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SD, standnonresponders to previous HBV vaccination schedules.
The included patients had a mean age of 47.3 (11) years.
The majority of the patients were men (86%) (Table 1).
Of the 100 included patients, 81% (95% CI 72–88%) of
the prior nonresponders revaccinated with Fendrix had a
successful serological response (Table 1). Male patients
responded in 81.4% with seroconversion, female patients
responded in 78.6% with seroconversion (P¼ 0.803).
The median nadir CD4þ cell count in the patients not
responding to Fendrix was 300 cells/ml. The median
nadir CD4þ cell count in the patients responding to
Fendrix was 303 cells/ml (P¼ 0.371). The CD4þ cell
count at the time of starting with Fendrix vaccination was
785 (210–1080) cells/ml in the nonresponding group
and 595 (240–1190) cells/ml in the responding group
(P¼ 0.170).
Univariate binary logistic regression analyses showed no
significant difference in nadir CD4þ cell count, age, sex,
BMI, viral load or the cumulative vaccination dosage
(Table 2). There appeared to be a trend towards a
significant association between CD4þ cell count and
CD8þ cell count and response to Fendrix.r Health, Inc. All rights reserved.
Result
86 (86)
47.310.9
79 (79.8)
25.7 (15.1 to 45.6)
2.0 (2 to 17)
ge) 300 (20 to 1040)
79 (83.2)
) 605 (210 to 1190)
) 810 (0 to 2645)
100), n (%) 4 (4)
100), n (%) 96 (96)
31 (38.8)
15 (18.8)
32 (40.0)
2 (2.6)
12 (12.4)
52 (53.6)
19 (19.6)
6 (6.2)
8 (8.2)
89
25 (28.1)
53 (59.6)
11 (12.4)
87
14 (16.1)
26 (29.9)
41 (47.1)
6 (6.9)
81 (81)
therapy; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI,
ard deviation.
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Table 2. Predictors of response to Fendrix (NU100).
Independent variable
Response to
Fendrix (n¼81)
No response to
Fendrix (n¼19)
Univariate
analysis, P value
Age (years, mean) 47.511.6 46.78.0 0.772
Sex (male, %) 86.4 84.2 0.803
BMI (kg/m2, median) 26.0 (15.0–45.6) 24.2 (17.8–34.8) 0.554
Nadir CD4þ (cells/ml, median)a 303.0 (20–900) 300.0 (20–1040) 0.626
Median CD4þ at start Fendrix (cells/ml) (range) 595.0 (240–1190) 785.0 (210–1080) 0.079
Median CD8þ at start Fendrix (cells/ml) (range) 1160.0 (0–2110) 780.0 (130–2645) 0.083
Median CD4þ/CD8þ ratio (range) 0.72 (0.18–4.38) 0.66 (0.14–3.89) 0.529
Viral load <50copies/ml at start Fendrix (%) 83.1 83.3 0.982
Number of previous vaccination schemesb n¼73 n¼16
Second series, n (%) 20 (27.4) 5 (31.3) 0.630
Third series, n (%) 45 (61.6) 8 (50.0) 0.337
>Third series, n (%) 8 (11.0) 3 (18.8) 0.609
Fendrix vaccination schemec n¼72 n¼15
Scheme 0 month (n, %) 11 (15.3) 3 (20.0) 0.576
Scheme 0–1–6 month (n, %) 23 (31.9) 3 (20.0) 0.206
Scheme 0–1–2–6 month (n, %) 34 (47.2) 7 (46.7) 0.356
Other (n, %) 6 (6.9) 4 (13.3) 0.625
Data are reported as mean SD or as median with range. ART, antiretroviral therapy; SD, standard deviation.
aOnly patients where the date of nadir CD4þ lies before start of Fendrix.
bNumber of previous vaccinations was missing for eight patients in the responding group and in three patients in the nonresponding group.
cVaccination schema was missing for seven patients in the responding group and two patients in the nonresponding group.Discussion
In this retrospective analysis of 100 patients with HIVand
nonresponding to prior hepatitis B vaccination, Fendrix
showed a high seroconversion rate of 81%, irrespective of
the Fendrix scheme used or the amount of vaccines given.
This is a remarkably high seroconversion rate in these
patients, as many of the patients had failed not only once,
but also a second or third hepatitis B vaccination series
before the Fendrix vaccination scheme. This result
confirms the seroconversion rate previously found in a
small study on the immunogenicity of Fendrix in 22
nonresponding adults with HIV, conducted by De Silva
et al. [16], which found a similar success rate of 81.8%. We
included 100 patients, making this study much larger.
These rates are higher than previously conducted studies
that tested other revaccination regimes. Rey et al. [17]
reported seroconversion rates in nonresponding patients
with HIV after they were revaccinated either with 20 or
40mg recombinant hepatitis B vaccine of 67 and 74%.
Pettit et al. [11] found a similar seroconversion rate of
66.7% after revaccination with 40mg Engerix-B.
In contrast with some previous studies, in which a lower
nadir CD4þ cell count, a lower CD4þ cell count at the
time of vaccination or a lower CD4þ/CD8þ cell ratio was
associated with a lower seroconversion rate [10,18,19],
we found no association between any of these parameters
and response to vaccination with Fendrix. This could be
explained by the relatively good immune status of our
cohort. In fact, in only four patients of our cohort, the
CD4þ cell count was below 350 cells/ml at the time of
vaccination (two in each group), thus precluding an
assessment of the effect of a low CD4þ cell count on
vaccination response. Unexpectedly, there appeared to be Copyright © 2019 Wolters Kluwer Ha trend towards a higher CD4þ cell count an lower CD8þ
cell count in the nonresponding group, and vice versa but,
because almost none of the patients had a low CD4þ cell
count, we doubt the clinical relevance of this finding.
Moreover, in our study, CD4þ/CD8þ cell ratio was
not significantly different between the responding and
nonresponding group.
We found no significant association between weight, age
or viral load, in contrast to previous studies in this patient
population [9,10] Furthermore, cumulative doses of
Fendrix were not associated with a higher chance of
seroconversion. Based on these findings, it seems that the
increased rate of seroconversion with Fendrix might be
attributable to the composition and immunogenicity
of Fendrix.
The main strength of this study is that we were able to
assess the seroconversion rate after Fendrix vaccination in
the largest group of nonresponding patients with HIV
thus far. This also allowed us to study the effect of the
number and type of vaccinations used before Fendrix on
seroconversion rate. As a result, we found that the number
of dosages before Fendrix were not associated with higher
chance of seroconversion.
The study has several limitations, including its retrospec-
tive nature. There was no standard protocol for
revaccination with Fendrix, patients had used a variety
of types of revaccinations strategies with Fendrix, for
example, single and double dosages and different
revaccination schemes. However, we found no significant
association between the revaccination strategy and
response to Fendrix vaccination. We also did not record
the exact titer of anti-HBs after revaccination withealth, Inc. All rights reserved.
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below 10 IU/ml.
In conclusion, vaccination with Fendrix has a high
success rate of 81% irrespective of nadir CD4þ cell count
or CD4þ cell count at the time of revaccination. Based on
this high success rate, we recommend a prospective trial,
in which patients with HIVare vaccinated with Fendrix as
first-line hepatitis B vaccination or to the current standard
hepatitis B vaccination, including a cost-effectiveness
analysis. In the meantime, we advise considering the use
of Fendrix as a revaccination strategy after failure of the
first-line vaccination strategy.Acknowledgements
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